Macrophage activation syndrome in the era of biologic therapy

Alexei A. Grom, Anna Carin Horne, Fabrizio de Benedetti

Research output: Contribution to journalArticlepeer-review


Macrophage activation syndrome (MAS) refers to acute overwhelming inflammation caused by a 'cytokine storm'. Although increasingly recognized as a life-threatening complication of various rheumatic diseases, clinically, MAS is strikingly similar to primary and secondary forms of haemophagocytic lymphohistiocytosis (HLH). Not surprisingly, many rheumatologists prefer the term secondary HLH rather than MAS to describe this condition, and efforts to change the nomenclature are in progress. The pathophysiology of MAS remains elusive, but observations in animal models, as well as data on the effects of new anticytokine therapies on rates and clinical presentations of MAS in patients with systemic juvenile idiopathic arthritis (sJIA), provide clues to the understanding of this perplexing clinical phenomenon. In this Review, we explore the latest available evidence and discuss potential diagnostic challenges in the era of increasing use of biologic therapies.

Original languageEnglish
JournalNature Reviews Rheumatology
Publication statusAccepted/In press - Mar 24 2016

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Macrophage activation syndrome in the era of biologic therapy'. Together they form a unique fingerprint.

Cite this